LifeSpan Vision Ventures Invests in Remedium Bio

NORWALK, Conn., Sept. 10, 2024 -- LifeSpan Vision Ventures has recently announced a significant investment in Remedium Bio, a biotechnology company pioneering an innovative gene therapy platform named Prometheus™. This platform represents a groundbreaking approach to gene therapy, offering an adjustable-dose system that can replace various multi-protein injection treatments with a single, subcutaneous injection. This method promises increased safety, localization, durability, and reduced costs compared to traditional protein-based therapies. Unlike repeated protein injections, Prometheus™ ensures stable and consistent protein expression, avoiding the concentration spikes that compromise the safety and effectiveness of other treatments.

The newly acquired funding will advance Remedium Bio's lead candidate, RMD-1202, towards its Phase 1 clinical trials. RMD-1202 is designed to deliver a GLP-1 receptor agonist, which has shown superior results in weight loss, glycemic control, and insulin response compared to daily GLP-1 protein injections. This candidate also potentially offers improved safety and tolerability. Remedium's Prometheus™ platform is versatile enough to deliver a broad spectrum of proteins, ranging from peptides to antibodies. The company is actively developing additional gene therapies targeting musculoskeletal, immunology, and neurology disorders.

Andrew Worden, a Founding Partner at LifeSpan Vision Ventures, expressed his enthusiasm for this partnership, stating, "Our goal is to invest in companies that contribute to extending healthspan and addressing age-related health challenges. Remedium’s technology has vast potential across numerous age-related diseases, opening up new markets for gene therapy. We are thrilled to support Frank and his innovative team in propelling the company to greater heights."

Frank Luppino, the President and CEO of Remedium, shared his excitement about the collaboration, "We are very enthusiastic to have LifeSpan Vision Ventures on board as an investor. Our Prometheus™ platform marks a significant milestone in genetic medicine, addressing substantial unmet needs related to aging. LifeSpan's expertise in science and experience in nurturing innovative companies makes them an ideal partner as we embark on this exciting phase of development."

Remedium Bio is dedicated to creating treatments for significant unmet clinical needs. Their revolutionary gene therapy platform ensures safe, effective, and durable delivery of therapeutic genes while allowing for straightforward post-treatment dose adjustments. The Prometheus™ platform can replace a wide range of subcutaneously administered protein treatments with a single, cost-effective injection. This platform offers unprecedented specificity and remains localized to the injection site, providing a safer and more durable alternative to current protein-based treatments. Remedium's pipeline includes several groundbreaking treatments showing unprecedented efficacy in endocrinology (such as weight loss and type 2 diabetes), immunology, neurology, and musculoskeletal diseases.

LifeSpan Vision Ventures is a venture capital firm focused on investments in the aging and longevity sectors. Their mission is to support and expedite the development of innovative therapies that extend healthspan, enhance the quality of life as people age, and tackle age-related health challenges. Through strategic partnerships and investments, LifeSpan Vision Ventures aims to foster a future where aging is characterized by vitality, resilience, and numerous possibilities.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!